Literature DB >> 18473173

Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice.

Graziano Pinna1, Roberto Carlos Agis-Balboa, Fabio Pibiri, Marianela Nelson, Alessandro Guidotti, Erminio Costa.   

Abstract

The neurosteroid allopregnanolone is a potent positive allosteric modulator of GABA action at GABA(A) receptors. Allopregnanolone is synthesized in the brain from progesterone by the sequential action of 5alpha-reductase type I (5alpha-RI) and 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD). 5alpha-RI and 3alpha-HSD are co-expressed in cortical, hippocampal, and olfactory bulb glutamatergic neurons and in output neurons of the amygdala, thalamus, cerebellum, and striatum. Neither 5alpha-RI nor 3alpha-HSD mRNAs is expressed in glial cells or in cortical or hippocampal GABAergic interneurons. It is likely that allopregnanolone synthesized in principal output neurons locally modulates GABA(A) receptor function by reaching GABA(A) receptor intracellular sites through lateral membrane diffusion. This review will focus on the behavioral effects of allopregnanolone on mouse models that are related to a sexually dimorphic regulation of brain allopregnanolone biosynthesis. Animal models of psychiatric disorders, including socially isolated male mice or mice that receive a long-term treatment with anabolic androgenic steroids (AAS), show abnormal behaviors such as altered fear responses and aggression. In these animal models, the cortico-limbic mRNA expression of 5alpha-RI is regulated in a sexually dimorphic manner. Hence, in selected glutamatergic pyramidal neurons of the cortex, CA3, and basolateral amygdala and in granular cells of the dentate gyrus, mRNA expression of 5alpha-RI is decreased, which results in a downregulation of allopregnanolone content. In contrast, 5alpha-RI mRNA expression fails to change in the striatum medium spiny neurons and in the reticular thalamic nucleus neurons, which are GABAergic.By manipulating allopregnanolone levels in glutamatergic cortico-limbic neurons in opposite directions to improve [using the potent selective brain steroidogenic stimulant (SBSS) S-norfluoxetine] or induce (using the potent 5alpha-RI inhibitor SKF 105,111) behavioral deficits, respectively, we have established the fundamental role of cortico-limbic allopregnanolone levels in the sexually dimorphic regulation of aggression and fear. By selectively targeting allopregnanolone downregulation in glutamatergic cortico-limbic neurons, i.e., by improving the response of GABA(A) receptors to GABA, new therapeutics would offer appropriate and safe management of psychiatric conditions, including impulsive aggression, irritability, irrational fear, anxiety, posttraumatic stress disorders, and depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473173     DOI: 10.1007/s11064-008-9718-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  129 in total

1.  Intrinsic synaptic circuitry of the amygdala.

Authors:  Asla Pitkänen; Mia Savander; Nina Nurminen; Aarne Ylinen
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

Review 2.  Social isolation stress-induced aggression in mice: a model to study the pharmacology of neurosteroidogenesis.

Authors:  Kinzo Matsumoto; Graziano Pinna; Giuli Puia; Alessandro Guidotti; Erminio Costa
Journal:  Stress       Date:  2005-06       Impact factor: 3.493

3.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.

Authors:  L D Griffin; S H Mellon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 4.  Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs.

Authors:  Maria Luisa Barbaccia
Journal:  Crit Rev Neurobiol       Date:  2004

Review 5.  Anabolic androgenic steroids and forebrain GABAergic transmission.

Authors:  L P Henderson; C A A Penatti; B L Jones; P Yang; A S Clark
Journal:  Neuroscience       Date:  2005-11-28       Impact factor: 3.590

6.  Chronic administration of anabolic androgenic steroid alters murine thyroid function.

Authors:  Rodrigo S Fortunato; Michelle P Marassi; Elen A Chaves; José Hamilton M Nascimento; Doris Rosenthal; Denise P Carvalho
Journal:  Med Sci Sports Exerc       Date:  2006-02       Impact factor: 5.411

Review 7.  Neurosteroids in the context of stress: implications for depressive disorders.

Authors:  Susan S Girdler; Rebecca Klatzkin
Journal:  Pharmacol Ther       Date:  2007-05-24       Impact factor: 12.310

8.  Prenatal exposure to testosterone and functional cerebral lateralization: a study in same-sex and opposite-sex twin girls.

Authors:  Celina C C Cohen-Bendahan; Jan K Buitelaar; Stephanie H M van Goozen; Peggy T Cohen-Kettenis
Journal:  Psychoneuroendocrinology       Date:  2004-08       Impact factor: 4.905

9.  Projections of the ventral subiculum to the amygdala, septum, and hypothalamus: a PHAL anterograde tract-tracing study in the rat.

Authors:  N S Canteras; L W Swanson
Journal:  J Comp Neurol       Date:  1992-10-08       Impact factor: 3.215

10.  Response of serum hormones to androgen administration in power athletes.

Authors:  M Alén; M Reinilä; R Vihko
Journal:  Med Sci Sports Exerc       Date:  1985-06       Impact factor: 5.411

View more
  46 in total

1.  Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse.

Authors:  Beth A Costine; Joseph G Oberlander; Matthew C Davis; Carlos A A Penatti; Donna M Porter; Robert N Leaton; Leslie P Henderson
Journal:  Psychoneuroendocrinology       Date:  2010-05-26       Impact factor: 4.905

2.  Type 1 5α-reductase may be required for estrous cycle changes in affective behaviors of female mice.

Authors:  Carolyn J Koonce; Alicia A Walf; Cheryl A Frye
Journal:  Behav Brain Res       Date:  2011-09-21       Impact factor: 3.332

3.  Neurobehavioral abnormalities in a brain-specific NADPH-cytochrome P450 reductase knockout mouse model.

Authors:  C Fang; V J Bolivar; J Gu; W Yang; S O Zeitlin; X Ding
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

4.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 5.  Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors.

Authors:  Marie M Onakomaiya; Leslie P Henderson
Journal:  Psychopharmacology (Berl)       Date:  2016-01-12       Impact factor: 4.530

6.  S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice.

Authors:  Marianela Nelson; Graziano Pinna
Journal:  Neuropharmacology       Date:  2010-10-29       Impact factor: 5.250

7.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

8.  Progesterone reduces the effect of the serotonin 1B/1D receptor antagonist, GR 127935, on lordosis behavior.

Authors:  Lynda Uphouse; Cindy Hiegel; Jutatip Guptarak; Navin Maswood
Journal:  Horm Behav       Date:  2008-10-08       Impact factor: 3.587

9.  Role of social encounter-induced activation of prefrontal serotonergic systems in the abnormal behaviors of isolation-reared mice.

Authors:  Yukio Ago; Ryota Araki; Tatsunori Tanaka; Asuka Sasaga; Saki Nishiyama; Kazuhiro Takuma; Toshio Matsuda
Journal:  Neuropsychopharmacology       Date:  2013-02-20       Impact factor: 7.853

10.  Influence of 17beta-estradiol and progesterone on GABAergic gene expression in the arcuate nucleus, amygdala and hippocampus of the rhesus macaque.

Authors:  Nigel C Noriega; Dominique H Eghlidi; Vasilios T Garyfallou; Steven G Kohama; Sharon G Kryger; Henryk F Urbanski
Journal:  Brain Res       Date:  2009-10-13       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.